HIK vs. HCM, INDV, CTEC, GNS, SN, BMK, APH, BXP, ANCR, and AGY
Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), ConvaTec Group (CTEC), Genus (GNS), Smith & Nephew (SN), Benchmark (BMK), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), and Allergy Therapeutics (AGY). These companies are all part of the "medical" sector.
HUTCHMED (LON:HCM) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.
Hikma Pharmaceuticals received 602 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.62% of users gave Hikma Pharmaceuticals an outperform vote.
HUTCHMED has a net margin of 12.03% compared to HUTCHMED's net margin of 6.61%. Hikma Pharmaceuticals' return on equity of 14.65% beat HUTCHMED's return on equity.
Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than HUTCHMED, indicating that it is currently the more affordable of the two stocks.
In the previous week, HUTCHMED and HUTCHMED both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.67 beat HUTCHMED's score of 0.50 indicating that HUTCHMED is being referred to more favorably in the media.
33.7% of HUTCHMED shares are owned by institutional investors. Comparatively, 38.8% of Hikma Pharmaceuticals shares are owned by institutional investors. 42.9% of HUTCHMED shares are owned by insiders. Comparatively, 30.7% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
HUTCHMED has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.
Hikma Pharmaceuticals has a consensus price target of GBX 2,068.75, suggesting a potential upside of 5.55%. Given HUTCHMED's higher probable upside, analysts clearly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.
Summary
HUTCHMED and Hikma Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Hikma Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hikma Pharmaceuticals Competitors List
Related Companies and Tools
